MAFA and plasma cell myeloma: This is confirmed by the combined treatment of LiCl, the inhibitor of GSK3β (4), and Dex, a major anti-MM agent, which strikingly upregulate HERC4 and inhibit MafA therefore suppressing MM cell proliferation and myeloma xenograft growth in mice.